Clinical Trials | December 17, 2024
Merck to discontinue KeyVibe and Keyform clinical trials
Merck has also decided to end the favezelimab clinical development program
Merck has also decided to end the favezelimab clinical development program
GFP is a common fusion protein tag that enables protein expression to be monitored, quantified, and localized within the complex environment of the cell
WINREVAIR met primary endpoint of time to first morbidity or mortality event for the treatment of patients with pulmonary arterial hypertension (PAH) functional class III or IV at high risk of mortality
The program aims to accelerate the development of 6 Indian innovations to improve ease of access to diagnostics and treatment monitoring
Combined capabilities to drive novel healthcare applications presented at MEDICA 2024
The partnership emphasises the introduction of renewable, bio-based materials into existing plastic applications to help reduce fossil resource dependency
Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI
The partnership marks a pivotal step towards developing new therapies for combating Sickle Cell Disease
Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun
AMR poses a critical threat to global public health undermining decades of progress made in the field of modern medicine
Subscribe To Our Newsletter & Stay Updated
